news, journals and articles from all over the world.
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
Read more
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Read more
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant program, this prestigious five-year grant will fund five clinical trials, all focused on a strategy for making some of the most common immunotherapies work for more cancer patients.
Read more
A new study from Washington University School of Medicine in St. Louis suggests that the age of certain immune cells used in immunotherapy plays a role in how effective it is. These cells — natural killer (NK) cells — appear to be more effective the earlier they are in development, opening the door to the possibility of an immunotherapy that would not utilize cells from the patient or a matched donor. Instead, they could be developed from existing supplies of what are called human pluripotent stem cells.
Read more
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.
Read more
A Ludwig Cancer Research study has identified a mechanism by which regulatory T cells, which suppress immune responses, adapt their metabolism to thrive in the harsh microenvironment of the tumor.
Read moreSummaries of recent Fred Hutch research studies, plus information on a press event at the upcoming AAAS annual meeting in Seattle.
Read moreA Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell—a family of promising immunotherapies for cancer—that can be switched on and off on demand.
Read moreThe Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study, sponsored by Regeneron, will examine outcomes for patients treated with Libtayo® (cemiplimab) — an immunotherapy treatment — prior to surgery and radiation therapy.
Read more
Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are participating in a first-in-patients clinical trial assessing VE800, a novel bacteria-containing therapy, in combination with the immunotherapy drug nivolumab. Laboratory research has suggested that VE800 may enhance the effectiveness of drugs like nivolumab.
Read more
Within weeks, CAR T cells targeting ovarian cancer cleared tumors in 70% of treated mice, shows study in Nature Biomedical Engineering. (Note: Images available for media use).
Read moreIn patients taking immune checkpoint inhibitors as a treatment for cancer, 17% experienced acute kidney injury (AKI), 8% experienced sustained AKI, and 3% had potential immune checkpoint inhibitor–related AKI.
• Use of proton pump inhibitors, which are commonly used to treat stomach ulcers or acid reflux, was associated with a higher risk of experiencing sustained AKI.